other products or firms not already on the agenda for which FDA participants have a financial interest, the participants' involvement and their exclusion will be noted for the record.
With respect to all other participants, we ask in the interest of fairness that they address all current or previous financial involvement with any firm whose product they may wish to comment upon.
DR. KIBBE: Thank you.
As is custom, we will ask the members sitting around the table to introduce themselves. Before we get started on that, we've gotten a couple of pieces of paper put out for the members to look at. One is a listing of the members and their expertise, and we would like you to correct that and turn it back in before you leave, if there are corrections, and a list of acronyms for your use. It's only 82 pages long, so you know the alphabet soup in Washington, D.C. has not gone away.
Let's start with Ajaz and go around the table and introduce. Yes, I know, Helen gets to talk first, but you get to introduce first.
DR. HUSSAIN: Ajaz Hussain, Deputy Director,